Molecular Partners (MOLN) Stock Forecast, Price Target & Predictions
MOLN Stock Forecast
Molecular Partners stock forecast is as follows: an average price target of $29.00 (represents a 457.69% upside from MOLN’s last price of $5.20) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
MOLN Price Target
The average price target for Molecular Partners (MOLN) is $29.00 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $29.00 to $29.00. This represents a potential 457.69% upside from MOLN's last price of $5.20.
MOLN Analyst Ratings
According to 2 Wall Street analysts, Molecular Partners's rating consensus is 'Buy'. The analyst rating breakdown for MOLN stock is 0 'Strong Buy' (0.00%), 1 'Buy' (50.00%), 1 'Hold' (50.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Molecular Partners Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Apr 27, 2022 | - | Leerink Partners | $29.00 | $13.89 | 108.78% | 457.69% |
The latest Molecular Partners stock forecast, released on Apr 27, 2022 by Leerink Partners company, set a price target of $29.00, which represents a 108.78% increase from the stock price at the time of the forecast ($13.89), and a 457.69% increase from MOLN last price ($5.20).
Molecular Partners Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $5.20 | $5.20 | $5.20 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of Molecular Partners stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Molecular Partners's last price of $5.20. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Apr 27, 2022 | SVB Leerink | Outperform | Outperform | Hold |
| Apr 27, 2022 | Credit Suisse | - | Neutral | Downgrade |
Molecular Partners's last stock rating was published by SVB Leerink on Apr 27, 2022. The company gave MOLN a "Outperform" rating, the same as its previous rate.
Molecular Partners Financial Forecast
Molecular Partners Revenue Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Jun 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | $3.05M | $2.69M | $2.34M | $11.75M | $172.78M | $1.77M | $3.53M | $3.21M | $815.00K | $2.34M | $2.34M |
| Avg Forecast | $201.62K | $349.06K | $795.75K | $2.70M | $380.83K | $1.40M | $1.60M | $1.65M | $4.17M | $3.27M | $11.72M | $165.59M | $14.01M | $2.03M | $2.02M | $3.73M | $13.61M | $13.33M |
| High Forecast | $201.62K | $349.06K | $795.96K | $2.70M | $380.83K | $1.40M | $1.60M | $1.65M | $4.17M | $3.27M | $11.72M | $165.59M | $14.01M | $2.03M | $2.02M | $3.73M | $13.61M | $13.33M |
| Low Forecast | $201.62K | $349.06K | $795.53K | $2.70M | $380.83K | $1.40M | $1.60M | $1.65M | $4.17M | $3.27M | $11.72M | $165.59M | $14.01M | $2.03M | $2.02M | $3.73M | $13.61M | $13.33M |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Surprise % | - | - | - | - | - | - | - | 1.85% | 0.65% | 0.71% | 1.00% | 1.04% | 0.13% | 1.73% | 1.59% | 0.22% | 0.17% | 0.18% |
Molecular Partners's average Quarter revenue forecast for Jun 23 based on 1 analysts is $1.60M, with a low forecast of $1.60M, and a high forecast of $1.60M. MOLN's average Quarter revenue forecast represents a -47.45% decrease compared to the company's last Quarter revenue of $3.05M (Mar 23).
Molecular Partners EBITDA Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Jun 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EBITDA | - | - | - | - | - | - | - | $-13.61M | $-13.72M | $-13.86M | $-5.56M | $153.26M | $-15.12M | $-12.18M | $-15.60M | $-17.86M | $-15.48M | $-15.48M |
| Avg Forecast | $-135.59K | $-234.74K | $-535.13K | $-1.82M | $-256.10K | $-938.89K | $-1.08M | $-1.11M | $-2.81M | $-2.20M | $-7.89M | $-111.48M | $-9.43M | $-1.37M | $-1.36M | $-2.51M | $-9.17M | $-8.98M |
| High Forecast | $-135.59K | $-234.74K | $-534.99K | $-1.82M | $-256.10K | $-938.89K | $-1.08M | $-1.11M | $-2.81M | $-2.20M | $-7.89M | $-111.48M | $-9.43M | $-1.37M | $-1.36M | $-2.51M | $-9.17M | $-8.98M |
| Low Forecast | $-135.59K | $-234.74K | $-535.28K | $-1.82M | $-256.10K | $-938.89K | $-1.08M | $-1.11M | $-2.81M | $-2.20M | $-7.89M | $-111.48M | $-9.43M | $-1.37M | $-1.36M | $-2.51M | $-9.17M | $-8.98M |
| Surprise % | - | - | - | - | - | - | - | 12.28% | 4.89% | 6.29% | 0.70% | -1.37% | 1.60% | 8.89% | 11.49% | 7.12% | 1.69% | 1.72% |
1 analysts predict MOLN's average Quarter EBITDA for Jun 22 to be $-7.89M, with a high of $-7.89M and a low of $-7.89M. This is -105.15% lower than Molecular Partners's previous annual EBITDA (Mar 22) of $153.26M.
Molecular Partners Net Income Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Jun 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Net Income | - | - | - | - | - | - | - | $-15.32M | $-19.91M | $-11.95M | $-2.67M | $153.13M | $-17.91M | $-11.69M | $-17.63M | $-14.41M | $-15.69M | $-15.69M |
| Avg Forecast | $-12.63M | $-17.54M | $39.90M | $47.38M | $-28.71M | $42.24M | $35.46M | $43.42M | $-20.13M | $-21.44M | $-20.84M | $-20.14M | $-18.90M | $-18.56M | $-19.07M | $-24.74M | - | - |
| High Forecast | $-12.63M | $-17.54M | $39.90M | $47.38M | $-28.71M | $42.24M | $35.46M | $43.42M | $-20.13M | $-21.44M | $-20.84M | $-20.14M | $-18.90M | $-18.56M | $-19.07M | $-24.74M | - | - |
| Low Forecast | $-12.63M | $-17.54M | $39.90M | $47.38M | $-28.71M | $42.24M | $35.46M | $43.42M | $-20.13M | $-21.44M | $-20.84M | $-20.14M | $-18.90M | $-18.56M | $-19.07M | $-24.74M | - | - |
| Surprise % | - | - | - | - | - | - | - | -0.35% | 0.99% | 0.56% | 0.13% | -7.60% | 0.95% | 0.63% | 0.92% | 0.58% | - | - |
Molecular Partners's average Quarter net income forecast for Jun 22 is $-20.84M, with a range of $-20.84M to $-20.84M. MOLN's average Quarter net income forecast represents a -113.61% decrease compared to the company's last Quarter net income of $153.13M (Mar 22).
Molecular Partners SG&A Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Jun 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| SG&A | - | - | - | - | - | - | - | $5.44M | $5.03M | $5.56M | $5.48M | $5.76M | $4.59M | $4.69M | $4.29M | $3.34M | $2.77M | $2.77M |
| Avg Forecast | $260.16K | $450.43K | $1.03M | $3.48M | $491.42K | $1.80M | $2.07M | $2.13M | $5.39M | $4.22M | $15.12M | $213.67M | $18.08M | $2.62M | $2.60M | $4.81M | $17.57M | $17.20M |
| High Forecast | $260.16K | $450.43K | $1.03M | $3.48M | $491.42K | $1.80M | $2.07M | $2.13M | $5.39M | $4.22M | $15.12M | $213.67M | $18.08M | $2.62M | $2.60M | $4.81M | $17.57M | $17.20M |
| Low Forecast | $260.16K | $450.43K | $1.03M | $3.48M | $491.42K | $1.80M | $2.07M | $2.13M | $5.39M | $4.22M | $15.12M | $213.67M | $18.08M | $2.62M | $2.60M | $4.81M | $17.57M | $17.20M |
| Surprise % | - | - | - | - | - | - | - | 2.56% | 0.93% | 1.32% | 0.36% | 0.03% | 0.25% | 1.79% | 1.65% | 0.70% | 0.16% | 0.16% |
Molecular Partners's average Quarter SG&A projection for Jun 23 is $2.07M, based on 1 Wall Street analysts, with a range of $2.07M to $2.07M. The forecast indicates a -62.00% fall compared to MOLN last annual SG&A of $5.44M (Mar 23).
Molecular Partners EPS Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Jun 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EPS | - | - | - | - | - | - | - | $-0.47 | $-0.61 | $-0.37 | $-0.08 | $4.74 | $-0.55 | $-0.36 | $-0.55 | $-0.49 | $-0.63 | $-0.63 |
| Avg Forecast | $-0.38 | $-0.53 | $1.20 | $1.43 | $-0.86 | $1.27 | $1.07 | $1.31 | $-0.61 | $-0.65 | $-0.63 | $-0.61 | $-0.57 | $-0.56 | $-0.57 | $-0.75 | - | - |
| High Forecast | $-0.38 | $-0.53 | $1.20 | $1.43 | $-0.86 | $1.27 | $1.07 | $1.31 | $-0.61 | $-0.65 | $-0.63 | $-0.61 | $-0.57 | $-0.56 | $-0.57 | $-0.75 | - | - |
| Low Forecast | $-0.38 | $-0.53 | $1.20 | $1.43 | $-0.86 | $1.27 | $1.07 | $1.31 | $-0.61 | $-0.65 | $-0.63 | $-0.61 | $-0.57 | $-0.56 | $-0.57 | $-0.75 | - | - |
| Surprise % | - | - | - | - | - | - | - | -0.36% | 1.01% | 0.57% | 0.13% | -7.81% | 0.97% | 0.64% | 0.96% | 0.66% | - | - |
According to 1 Wall Street analysts, Molecular Partners's projected average Quarter EPS for Jun 22 is $-0.63, with a low estimate of $-0.63 and a high estimate of $-0.63. This represents a -113.25% decrease compared to MOLN previous annual EPS of $4.74 (Mar 22).
Molecular Partners Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| PMVP | PMV Pharmaceuticals | $1.57 | $18.00 | 1046.50% | Buy |
| ANTX | AN2 Therapeutics | $1.30 | $8.75 | 573.08% | Buy |
| PEPG | PepGen | $4.40 | $29.50 | 570.45% | Buy |
| MOLN | Molecular Partners | $5.20 | $29.00 | 457.69% | Buy |
| OPT | Opthea | $3.28 | $14.00 | 326.83% | Buy |
| ANEB | Anebulo Pharmaceuticals | $1.52 | $6.00 | 294.74% | Buy |
| VIGL | Vigil Neuroscience | $3.05 | $11.00 | 260.66% | Buy |
| RZLT | Rezolute | $5.01 | $13.50 | 169.46% | Buy |
| ELYM | Eliem Therapeutics | $5.11 | $13.00 | 154.40% | Buy |
| MLYS | Mineralys Therapeutics | $12.60 | $30.00 | 138.10% | Buy |
| PHVS | Pharvaris | $20.50 | $39.67 | 93.51% | Buy |
| EWTX | Edgewise Therapeutics | $31.95 | $45.00 | 40.85% | Buy |
| TRDA | Entrada Therapeutics | $17.93 | $20.00 | 11.54% | Buy |
| CYT | Cyteir Therapeutics | $3.02 | $2.00 | -33.77% | Sell |